Scynexis (SCYX) EBT (2013 - 2026)
Scynexis' (SCYX) quarterly EBT came in at -$7.1 million in Q2 2026, down 2.98% on a YoY basis from -$7.3 million in Q2 2025, and up 56.78% quarter-over-quarter from -$16.4 million in Q1 2026.
Analysis
Scynexis (SCYX) EBT (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported EBT for 14 consecutive years, with -$7.1 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBT fell 2.98% year-over-year to -$7.1 million; the trailing twelve-month figure through Jun 2026 stood at -$19.8 million (changed 0.31% YoY), and the FY2025 full-year result was -$8.6 million, up 59.27% from the prior year.
- EBT improved to -$7.1 million in Q2 2026 per SCYX's latest filing, from -$16.4 million in the prior quarter.
- Across five years, EBT topped out at $122.3 million in Q2 2023 and bottomed at -$33.9 million in Q1 2023.
- Historically, EBT has averaged -$3.0 million across 5 years, with a median of -$7.8 million in 2025.
- The sharpest annual moves came in 2022 and 2023: EBT sank 4416.64% in 2022, then jumped 1016.15% in 2023.
- Over 5 years, EBT stood at -$14.4 million in 2022, then tumbled by 34.64% to -$19.4 million in 2023, then surged by 77.3% to -$4.4 million in 2024, then soared by 377.96% to $12.3 million in 2025, then sank by 157.84% to -$7.1 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$7.1 million, -$16.4 million, and $12.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 2.77 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -10.25 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 1.39 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 1.53 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 542.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -767.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 177.81 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 132.40 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -294.56 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | -7.09 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7.09 Mn |
| Mar 31, 2026 | -16.40 Mn |
| Dec 31, 2025 | 12.26 Mn |
| Sep 30, 2025 | -8.59 Mn |
| Jun 30, 2025 | -6.89 Mn |
| Mar 31, 2025 | -5.39 Mn |
| Dec 31, 2024 | -4.41 Mn |
| Sep 30, 2024 | -3.20 Mn |
| Jun 30, 2024 | -14.46 Mn |
| Mar 31, 2024 | 942,000.00 |
| Dec 31, 2023 | -19.43 Mn |
| Sep 30, 2023 | -1.76 Mn |
| Jun 30, 2023 | 122.26 Mn |
| Mar 31, 2023 | -33.88 Mn |
| Dec 31, 2022 | -14.43 Mn |
| Sep 30, 2022 | -29.58 Mn |
| Jun 30, 2022 | -13.35 Mn |
| Mar 31, 2022 | -10.15 Mn |
| Dec 31, 2021 | -29.29 Mn |
| Sep 30, 2021 | -655,000.00 |